01
Overview
GuanaRep is an early-stage biotechnology company focused on developing novel small molecule therapeutics that target guanine nucleotide exchange factors (GEFs). The company's primary research objective is to modulate intracellular signaling pathways that are frequently dysregulated in various forms of cancer. By inhibiting specific GEFs, GuanaRep aims to disrupt the activation of GTPases, thereby halting tumor growth and progression. The company is currently advancing its lead programs through pre-clinical validation to address unmet needs in oncology.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on GuanaRep.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GuanaRep.